Quality‐of‐Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient‐Oriented Outcomes and External Experts
International Journal of Dermatology · 2025
DOI: 10.1111/ijd.17668 ↗Kurz gefasst
Leitlinie in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Pavel V Chernyshov und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, National Medical University, Kyiv, Ukraine. Hauptthemen laut MEDLINE: Quality of Life, Epidermolysis Bullosa. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 127 Literaturangaben.
Abstract (Originalsprache)
In this paper, the European Academy of Dermatology and Venereology (EADV) Task Force on Quality of Life (QoL) and Patient‐Oriented Outcomes presents its position statements on health‐related (HR) QoL assessment in epidermolysis bullosa (EB). The EADV TF on QoL and Patient‐Oriented Outcomes recommends the use of the EB‐specific instrument QOLEB in patients over the age of 10 years and, in addition to the QOLEB, the use of iscorEB‐p in moderate‐to‐severe EB; the IntoDermQoL proxy instrument with its EB‐specific module should be used in children aged under 5 years. The EB‐specific instrument iscorEB‐p, and the dermatology‐specific instrument CDLQI may measure HRQoL in children with EB aged from 5 to 10 years. Dermatology‐specific and/or generic HRQoL instruments should be used to compare the impact on QoL of EB with other diseases; family QoL of patients with EB should be studied using the EB‐specific EB‐BoD, dermatology‐specific family measures, and/or generic family QoL instruments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, National Medical University, Kyiv, Ukraine.
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
- Department of Psychology, University of Zaragoza, Zaragoza, Spain.
- Department of Dermatology, University Hospital Erasme, Brussels, Belgium.
- Department of Dermatology, St George Hospital, UNSW, Sydney, Australia.
- Children's Hospital Zagreb, Zagreb, Croatia.
ORCID-Profile: Pavel V Chernyshov, Dedee F Murrell, Dimitra Koumaki, Matthias Augustin, Gregor B Jemec
Zitieren
APA
Chernyshov, P. V., Finlay, A. Y., Tomas-Aragones, L., Poot, F., Murrell, D. F., Pustisek, N., Svensson, A., Marron, S. E., Sampogna, F., Bewley, A., Salavastru, C., Koumaki, D., Suru, A., Yordanova, I. A., Zemskov, S., Tsymbaliuk, R., Ostapko, O., Augustin, M., Abeni, D., …, & Jemec, G. B. (2025). Quality‐of‐Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient‐Oriented Outcomes and External Experts. International Journal of Dermatology. https://doi.org/10.1111/ijd.17668
Vancouver
Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Murrell DF, Pustisek N, et al. Quality‐of‐Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient‐Oriented Outcomes and External Experts. International Journal of Dermatology. 2025. doi:10.1111/ijd.17668
BibTeX
@article{Chernyshov2025,
author = {Chernyshov, Pavel V and Finlay, Andrew Y and Tomas-Aragones, Lucia and Poot, Francoise and Murrell, Dedee F and Pustisek, Nives and Svensson, Ake and Marron, Servando E and Sampogna, Francesca and Bewley, Anthony and Salavastru, Carmen and Koumaki, Dimitra and Suru, Alina and Yordanova, Ivelina A and Zemskov, Serhiy and Tsymbaliuk, Ruslan and Ostapko, Olena and Augustin, Matthias and Abeni, Damiano and Szepietowski, Jacek C and Jemec, Gregor B},
title = {Quality‐of‐Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient‐Oriented Outcomes and External Experts},
journal = {International Journal of Dermatology},
year = {2025},
doi = {10.1111/ijd.17668}
}
EUVIMED